Coya Therapeutics Q3 net loss $4.0M, cash $39.8M post-raise; positive AD data, new CEO

Coya Therapeutics, Inc.

2024-Q3 EPS reported -$0.80 revenue$3,552,109

Net loss $4.0M in Q3 2024 (vs $3.4M prior); cash $31.1M (Sep) rose to $39.8M after capital raise.
Positive LD IL-2 data in mild-moderate Alzheimer's from investigator-initiated Phase 2 presented at CTAD24; patents filed for COYA 301/GLP-1 combo.
Arun Swaminathan appointed CEO effective Nov 1, 2024; Howard Berman transitions to Executive Chairman.
Aligned with FDA on non-clinical data for COYA-302 Phase 2b ALS trial; eligible for $8.4M milestone from Dr. Reddy's upon IND acceptance and dosing.
2025 catalysts: additional AD data Q1, ALS biomarker data Q2, FTD data 2H, and COYA-302 IND for FTD expected in 2H.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.